News
Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...
The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...
Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...
2d
Futurism on MSNEli Lilly's New Weight Loss Drug May Have the Worst Name in Pharmaceutical HistoryEli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...
Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
4d
24/7 Wall St. on MSNEli Lilly Will Be the Next $1 Trillion StockEli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...
1d
Zacks Investment Research on MSNIs Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...
The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results